Roche's Q1 pipeline cleanup claims PhII myelofi­bro­sis drug, ear­ly-stage MAGE-A4 work

More than three years af­ter Roche put down $390 mil­lion in cash to buy the biotech Prome­dior, the an­ti-fi­brot­ic drug at the cen­ter of the deal is gone from the pipeline.

Roche’s first-quar­ter pre­sen­ta­tion shows that a Phase II tri­al for zin­pen­trax­in al­fa (PRM-151) in myelofi­bro­sis has been cut — which a spokesper­son said was “due to port­fo­lio re-pri­ori­ti­sa­tion.” Dur­ing its last quar­ter­ly up­date, Roche had al­ready said that it was shut­ting down a Phase III study in id­io­path­ic pul­monary fi­bro­sis fol­low­ing a fu­til­i­ty analy­sis, but kept the myelofi­bro­sis study and an­tic­i­pat­ed a 2025 fil­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.